[Skip to Navigation]
Invited Commentary
October 7, 2021

Prognostic Factors for Dry Eye Disease Treatment Response in Clinical Trials

Author Affiliations
  • 1Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand
JAMA Ophthalmol. 2021;139(11):1208-1209. doi:10.1001/jamaophthalmol.2021.3946

Dry eye disease (DED) is a commonly encountered ophthalmic condition that is recognized to have significant effects on visual function, work productivity, and quality of life.1 In recent years, the highly heterogenous nature of the condition has become increasingly acknowledged, with the disease pathophysiology understood to involve the complex interaction of tear film homeostatic disturbances, ocular surface inflammation, and somatosensory pathways.1-3 Moreover, growing evidence of the poor levels of correlation between different markers of clinical DED signs and symptoms has been noted,2,4 which present a considerable diagnostic challenge and might partially contribute to the significant variation in current management patterns worldwide.1,5 In this context, the global consensus reports of the Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS II) recognized the importance of identifying prognostic factors for the therapeutic response of DED treatments to inform and optimize tailored management plans for individual patients,1 although scientific evidence in this area is limited.

Add or change institution